{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-015279","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.706050+00:00","generated_at":"2026-06-21T20:37:30.842631+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zomedica Q3 revenue $4.78M, net loss $5.0M; cash $158.5M","bullets":["Total revenue $4.78M (vs $0.02M Q3 2021); gross margin 75%.","Net loss $5.0M ($0.005/shr) vs $6.35M loss prior year.","Cash, equivalents, and AFS securities $158.5M at Sep 30, 2022.","Closed acquisitions of Revo 2 imaging assets and Assisi LOOP/Calmer Canine product lines.","PulseVet small animal unit sales up 225% YoY; TRUFORMA revenue up 350% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-015279","json":"https://secwatch.observer/filing/0001654954-22-015279.json","markdown":"https://secwatch.observer/filing/0001654954-22-015279.md","text":"https://secwatch.observer/filing/0001654954-22-015279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/0001654954-22-015279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:37:30.842631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7046a535859faa9dbfbca0871c10ebf15f7e7289","claim":"Zomedica Corp. reported the three months ended September 30, 2022 results: revenue $4.78 million, net income $5.00 million, EPS $0.005 per share.","evidence_excerpt":"Summary Third Quarter 2022 Results Zomedica reported a net loss for the three months ended September 30, 2022, of $5.00 million, or $0.005 per share, compared to a net loss of $6.35 million, or $0.006 per share, for the three months ended September 30, 2021, a decrease in losses of $1.35 million or approximately 21%. Zomedica reported a net loss for the nine months ended September 30, 2022, of $14.21 million, or $0.014 per share, compared to a net loss of $15.09 million, or $0.050 per share, after adjustments for equity charges, for the nine months ended September 30, 2021, a decrease in losses of $0.88 million or approximately 6%. Revenue for the three months ended September 30, 2022, was $4.78 million, compared to $0.02 million for the three months ended September 30, 2021, an increase of $4.76 million or approximately 23,800%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/0001654954-22-015279-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$4.78 million"},{"label":"Net income","value":"$5.00 million"},{"label":"EPS","value":"$0.005 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}